T3	total-participants 386 388	96
T4	intervention-participants 438 440	45
T5	control 445 452	placebo
T6	control-participants 461 463	51
T9	location 683 690	Finland
T10	outcome 882 908	discontinued the treatment
T11	iv-bin-percent 935 938	44%
T12	cv-bin-percent 946 949	22%
T13	outcome 1071 1092	endometrial thickness
T14	outcome 1317 1370	referrals to hospitals due to gynaecological findings
T15	outcome 1551 1571	discontinuation rate
T16	iv-cont-median 976 978	15
T18	iv-cont-median 1160 1163	4.3
T19	cv-cont-median 1171 1176	2.0mm
T17	cv-cont-median 986 995	30 months
T7	intervention 139 148	tamoxifen
T8	control 152 159	placebo
T1	condition 52 98	endometrial safety and gynaecological symptoms
T2	outcome 1476 1494	hysterectomy rates
T20	outcome 1504 1531	serious adverse event rates
